<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02881970</url>
  </required_header>
  <id_info>
    <org_study_id>2013-A01018-37</org_study_id>
    <secondary_id>2013-32</secondary_id>
    <nct_id>NCT02881970</nct_id>
  </id_info>
  <brief_title>Neonatal Hypoxic Ischemic Encephalopathy : Safety and Feasibility Study of a Curative Treatment With Autologous Cord Blood Stem Cells</brief_title>
  <acronym>NEOSTEM</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neonatal hypoxic-ischaemic encephalopathy is a dramatic perinatal complication due to brain&#xD;
      asphyxia. Neurological and neurosensory sequelae are frequent in survivors, due to neuronal&#xD;
      damage and loss.&#xD;
&#xD;
      Currently, only total or partial body hypothermia can partially prevent cell loss. However,&#xD;
      no treatment exists to restore neuronal functions.&#xD;
&#xD;
      Cord blood stem cells are a promising treatment for the near future.&#xD;
&#xD;
      The primary objective of this study is to test the safety and feasibility of a curative&#xD;
      treatment with autologous cord blood stem cell in neonatal hypoxic-ischaemic encephalopathy.&#xD;
&#xD;
      The secondary objectives are to test the efficacy of this curative treatment with cell with&#xD;
      neurogenic potential on the prevention of neurologic sequelae, as well as to test the optimum&#xD;
      timing of cell preparation administration&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2017</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse clinical or paraclinical event rates due to stem cell preparation</measure>
    <time_frame>2years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Preliminary efficacy as measured by neurodevelopmental function</measure>
    <time_frame>2years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Neonatal Hypoxic-ischaemic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Neonatal hypoxic-ischaemic encephalopathy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>autologous cord blood stem cell</intervention_name>
    <arm_group_label>Neonatal hypoxic-ischaemic encephalopathy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Term ≥ 36 weeks of gestation&#xD;
&#xD;
          -  and (2) :&#xD;
&#xD;
          -  a blood pH &lt; 7 with base deficit &gt; 12 mmol/l (at birth or within 60 minutes of age)&#xD;
&#xD;
          -  or a blood pH between 7,01 and 7,15, with additionnal criteria:&#xD;
&#xD;
          -  a history of acute perinatal event (e.g : abnormal fetal cardiac rate, cord prolapse,&#xD;
             uterine rupture, maternal hemorrhage)&#xD;
&#xD;
          -  and a 5 minutes Apgar score ≤ 5, or a continued need for resuscitation, including&#xD;
             endotracheal or mask ventilation at 5 min after birth.&#xD;
&#xD;
          -  signs of encephalopathy within 12 hours of age (Sarnat and Sarnat classification,&#xD;
             score ≥ 2)&#xD;
&#xD;
          -  ± abnormal electroencephalogram or aEEG within 12 hours of age&#xD;
&#xD;
          -  therapeutic hypothermia.&#xD;
&#xD;
          -  no maternal infection with VIH, HTLV 1 or 2, Hepatitis B or C virus.&#xD;
&#xD;
          -  maternal negative serology for syphilis&#xD;
&#xD;
          -  written parental consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  presence of known chromosomal anomaly.&#xD;
&#xD;
          -  presence of major congenital anomalies. severe intrauterine growth restriction (weight&#xD;
             &lt;1800g)&#xD;
&#xD;
          -  infants in extremis for whom no additional intensive therapy will be offered by&#xD;
             attending neonatologist.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CATHERINE GEINDRE</last_name>
    <role>Study Director</role>
    <affiliation>AP HM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Farid BOUBRED</last_name>
    <email>farid.boubrd@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>FARID BOUBRED</last_name>
      <email>farid.boubred@ap-hm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>August 24, 2016</study_first_submitted>
  <study_first_submitted_qc>August 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2016</study_first_posted>
  <last_update_submitted>August 24, 2016</last_update_submitted>
  <last_update_submitted_qc>August 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

